[Foliculitis in a patient with Hodkins disease]

Enferm Infecc Microbiol Clin. 2003 Feb;21(2):101-2. doi: 10.1016/s0213-005x(03)72891-2.
[Article in Spanish]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Carmustine / administration & dosage
  • Carmustine / adverse effects
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Dacarbazine / administration & dosage
  • Dermatomycoses / drug therapy
  • Dermatomycoses / etiology*
  • Dermatomycoses / microbiology
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Folliculitis / drug therapy
  • Folliculitis / etiology*
  • Folliculitis / microbiology
  • Hodgkin Disease / complications*
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / radiotherapy
  • Humans
  • Itraconazole / therapeutic use
  • Malassezia / isolation & purification*
  • Male
  • Melphalan / administration & dosage
  • Melphalan / adverse effects
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / etiology*
  • Opportunistic Infections / microbiology
  • Vinblastine / administration & dosage

Substances

  • Antifungal Agents
  • Cytarabine
  • Bleomycin
  • Itraconazole
  • Vinblastine
  • Etoposide
  • Dacarbazine
  • Dexamethasone
  • Doxorubicin
  • Melphalan
  • Carmustine

Supplementary concepts

  • Dexa-BEAM protocol